Ting Wu

1838 North Guangzhou Ave, Guangzhou510515, PR China
Puerto Rico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Discovery of a Novel Thienopyrimidine Derivative as a Potent Dual URAT1/GLUT9 Inhibitor with Enhanced Urate-Lowering Efficacy, Superior Pharmacokinetics, and Favorable Safety Profile for Gout and Hyperuricemia.

Discovery of a Novel Thienopyrimidine Derivative as a Potent Dual URAT1/GLUT9 Inhibitor with Enhanced Urate-Lowering Efficacy, Superior Pharmacokinetics, and Favorable Safety Profile for Gout and Hyperuricemia.

Journal: Journal of medicinal chemistry

Published: May 06, 2026

GSH-responsive self-assembled nanoplatform synergistically enhances cuproptosis through metabolic reprogramming and oxidative stress amplification.

GSH-responsive self-assembled nanoplatform synergistically enhances cuproptosis through metabolic reprogramming and oxidative stress amplification.

Journal: Materials today. Bio

Published: February 10, 2026

NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?

NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?

Journal: Cell death & disease

Published: June 23, 2025

TRP channels at the crossroads of metabolism and immunity: ion-metabolite coupling in inflammation and disease.

TRP channels at the crossroads of metabolism and immunity: ion-metabolite coupling in inflammation and disease.

Journal: Metabolism: clinical and experimental

Published: June 12, 2025

Loss of Urat1 exacerbates APAP-induced liver injury in mice.

Loss of Urat1 exacerbates APAP-induced liver injury in mice.

Journal: Toxicology

Published: October 14, 2024

Substantial spillover burden of rat hepatitis E virus in humans.

Substantial spillover burden of rat hepatitis E virus in humans.

Journal: Nature communications

Published: July 22, 2024

Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production.

Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production.

Journal: Chemico-biological interactions

Published: April 10, 2024

Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.

Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.

Journal: European journal of medicinal chemistry

Published: January 25, 2024

Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1.

Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1.

Journal: European journal of pharmacology

Published: October 27, 2023

SYNJ1 rescues motor functions in hereditary and sporadic Parkinson's disease mice by upregulating TSP-1 expression.

SYNJ1 rescues motor functions in hereditary and sporadic Parkinson's disease mice by upregulating TSP-1 expression.

Journal: Behavioural brain research

Published: March 28, 2023

Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.

Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.

Journal: European journal of medicinal chemistry

Published: August 16, 2022

A new method for C(sp2)-H sulfonylmethylation with glyoxylic acid and sodium sulfinates.

A new method for C(sp2)-H sulfonylmethylation with glyoxylic acid and sodium sulfinates.

Journal: Organic & biomolecular chemistry

Published: February 10, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026